ATE260931T1 - Verfahren zur identifizierung von verbindungen mit verminderter systemischer aktivität - Google Patents

Verfahren zur identifizierung von verbindungen mit verminderter systemischer aktivität

Info

Publication number
ATE260931T1
ATE260931T1 AT98934998T AT98934998T ATE260931T1 AT E260931 T1 ATE260931 T1 AT E260931T1 AT 98934998 T AT98934998 T AT 98934998T AT 98934998 T AT98934998 T AT 98934998T AT E260931 T1 ATE260931 T1 AT E260931T1
Authority
AT
Austria
Prior art keywords
reduced systemic
identifying compounds
human
systemic activity
compounds
Prior art date
Application number
AT98934998T
Other languages
English (en)
Inventor
Keith Biggadike
Richard Martyn Angell
Panayiotis Alexandro Procopiou
Rosanne Mary Farrell
Usha V Ramesh
Duncan Stuart Holmes
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9713818.4A external-priority patent/GB9713818D0/en
Priority claimed from GBGB9713819.2A external-priority patent/GB9713819D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE260931T1 publication Critical patent/ATE260931T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/005—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT98934998T 1997-06-30 1998-06-26 Verfahren zur identifizierung von verbindungen mit verminderter systemischer aktivität ATE260931T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9713818.4A GB9713818D0 (en) 1997-06-30 1997-06-30 Compounds
GBGB9713819.2A GB9713819D0 (en) 1997-06-30 1997-06-30 Method of reducing the systemic effects of compounds
PCT/EP1998/003905 WO1999001467A2 (en) 1997-06-30 1998-06-26 Therapeutically active compounds with low systemic activity due to reduce half life

Publications (1)

Publication Number Publication Date
ATE260931T1 true ATE260931T1 (de) 2004-03-15

Family

ID=26311812

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98934998T ATE260931T1 (de) 1997-06-30 1998-06-26 Verfahren zur identifizierung von verbindungen mit verminderter systemischer aktivität

Country Status (7)

Country Link
EP (1) EP0998484B1 (de)
JP (2) JP2000513380A (de)
AT (1) ATE260931T1 (de)
AU (1) AU8439998A (de)
DE (1) DE69822164T2 (de)
ES (1) ES2215310T3 (de)
WO (1) WO1999001467A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
SI1775305T1 (sl) 2000-08-05 2015-01-30 Glaxo Group Limited S-fluorometil ester 6alfa,9alfa-difluoro-17alfa-((2-furanilkarboksil)oksi)- 11beta-hidroksi-16alfa-metil-3-okso-androst-1,4-dien-17-karbotiojske kisline kot protivnetno sredstvo
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6656946B2 (en) 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6403580B1 (en) 2000-08-26 2002-06-11 Boehringer Ingelheim Pharma Kg Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US6617329B2 (en) 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
KR100831534B1 (ko) 2001-04-30 2008-05-22 글락소 그룹 리미티드 17.알파 위치에 시클릭 에스테르기를 지닌 항염증성의안드로스탄의 17.베타.-카르보티오에이트 에스테르 유도체
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
TWI374147B (en) 2006-01-27 2012-10-11 Sun Pharma Advance Res Company Ltd Novel 11β-hydroxyandrosta-4-ene-3-ones
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2019073775A1 (ja) 2017-10-11 2019-04-18 ダイキン工業株式会社 不飽和基を有する環状カーボネートの製造方法及び新規環状カーボネート

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093721A (en) * 1974-08-30 1978-06-06 Glaxo Laboratories Limited Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof
SE449106B (sv) * 1980-07-10 1987-04-06 Otsuka Pharma Co Ltd Steroid med anti-inflammatorisk verkan samt komposition innehallande denna
DE3133631A1 (de) * 1981-08-21 1983-03-03 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue kortikoide ihre herstellung und verwendung
US4935421A (en) * 1981-11-12 1990-06-19 E. I. Du Pont De Nemours And Company 2-hydroxypropylamine aryl ester derivatives and pharmaceutical use
US4906661A (en) * 1981-11-12 1990-03-06 E. I. Du Pont De Nemours And Company Esters of aryloxypropanolamine derivatives
EP0174956B1 (de) * 1984-03-14 1990-08-16 BODOR, Nicholas S. Sanfte beta-adrenergische blockierende agenzien
IL78144A0 (en) * 1985-04-04 1986-07-31 Draco Ab Novel androstane-17beta-carboxylic acid esters
JP3176075B2 (ja) * 1991-03-04 2001-06-11 帝國製薬株式会社 新規なステロイド誘導体
EP0664788A1 (de) * 1992-10-16 1995-08-02 Byk Nederland BV Substituierte ethanolaminester
US5629193A (en) * 1994-07-05 1997-05-13 Human Genome Sciences, Inc. Paraoxonase
US5775329A (en) * 1995-06-07 1998-07-07 Gensia, Inc. Method and compounds for diagnosing coronary artery disease
WO1997024368A1 (en) * 1995-12-29 1997-07-10 Glaxo Group Limited 17beta-(2-oxo-tetrahydrofuran-4-yl)-thio-androstane derivatives (17beta-(gamma-butyric acid lactone)-thio derivatives) for the treatment of inflammation and pharmaceutical compositions and a process for the production thereof
EP0876393B1 (de) * 1995-12-29 2000-07-05 Glaxo Group Limited 21-[2-oxo-tetrahydrofuran]-thio pregnan derivative, ein verfahren zu ihrer herstellung und pharmazeutische präparate davon
CN1133643C (zh) * 1995-12-29 2004-01-07 葛兰素集团有限公司 17-β-羧基,羰基硫代以及酰胺雄甾烷衍生物的内酯衍生物

Also Published As

Publication number Publication date
AU8439998A (en) 1999-01-25
JP2002322168A (ja) 2002-11-08
DE69822164T2 (de) 2005-04-14
WO1999001467A3 (en) 1999-05-14
WO1999001467A2 (en) 1999-01-14
EP0998484A1 (de) 2000-05-10
JP2000513380A (ja) 2000-10-10
ES2215310T3 (es) 2004-10-01
DE69822164D1 (de) 2004-04-08
EP0998484B1 (de) 2004-03-03

Similar Documents

Publication Publication Date Title
ATE260931T1 (de) Verfahren zur identifizierung von verbindungen mit verminderter systemischer aktivität
ATE442851T1 (de) 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a
DE3583008D1 (de) Pharmazeutische zusammensetzungen von dihydrocodeine/ibuprofen und verfahren.
BG46601A3 (bg) Метод за получаване на авермектинови производни
ATE171625T1 (de) Therapeutische verwendung von actin-bindenden verbindungen
DE3581407D1 (de) Bewahrung lebender gewebe.
ATE240744T1 (de) Verwendung von csf-1-inhibitoren
DE3575076D1 (de) Katheter fuer rueckinfusion von pharmazeutischen agenten.
DE3689943D1 (de) Degradierte Spezies eines Gewebeplasminogenaktivators, pharmazeutische Zubereitung und Verfahren zur Herstellung derselben.
DE69836139D1 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
NO862096L (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende vevsplasminogenaktivator.
DE3650358D1 (de) Diphosphonate enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Arthrosis.
DE3682229D1 (de) Zur stimulierung der traenensekretion verwendbare pharmazeutische praeparate.
DE3676601D1 (de) Mittel zur injektion von aktiviertem vitamin-d3.
BE904863A (fr) Systeme d'application endonasal.
SE8303003L (sv) Medel for att oka antitumorverkan hos antitumormedel
MY104006A (en) 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases.
DE3687097D1 (de) Therapeutisches mittel zur behandlung haematopoietischer krankheiten.
NO863373D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminosyre derivater.
DK325289A (da) Strontiumsalt, fremgangsmaade til fremstilling heraf samt farmaceutiske midler indeholdende saltet
ATE90359T1 (de) Peptide.
DK109590A (da) Biologisk aktivt protein
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
DE3581650D1 (de) Derivat von p-aminophenol mit mucrosekretolytischer fluessiger und antipyretischer wirksamkeit, dessen verfahren zur herstellung und dessen pharmazeutische zusammensetzungen.
FI911269A7 (fi) Menetelmä ja koostumus aktiivisten aineiden lisääntyneen pitoisuuden aikaansaamiseksi iholla iontoforeesin avulla

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties